

Supplementary Tables

Supplementary Table 1: Comorbid psychiatric and nervous system disorders at baseline (modified intent-to-treat population)

	Total (N=305)	LOCF endpoint symptomatic remission	
		Yes (n=172)	No (n=133)
Psychiatric disorders, n (%)	10 (3.3)	2 (1.2)	6 (6.0)
Anxiety/Anxiety disorder	2 (0.7)	1 (0.6)	1 (0.8)
Depression	2 (0.7)	1 (0.6)	1 (0.8)
Drug use disorder	1 (0.3)	0	1 (0.8)
Insomnia	4 (1.3)	1 (0.6)	3 (2.3)
Loss of libido	1 (0.3)	0	1 (0.8)
Mood altered	1 (0.3)	0	1 (0.8)
Psychogenic erectile dysfunction	1 (0.3)	1 (0.6)	0
Psychosexual disorder	1 (0.3)	0	1 (0.8)
Nervous system disorders, n (%)	20 (6.6)	7(4.1)	13 (9.8)
Akathisia	5 (1.6)	0	5 (3.8)
Bradykinesia	1 (0.3)	1 (0.6)	0
Dyskinesia	1 (0.3)	0	1 (0.8)
Epilepsy	1 (0.3)	0	1 (0.8)
Extrapyramidal disorder	4 (1.3)	3 (1.7)	1 (0.8)
Headache	4 (1.3)	2 (1.2)	2 (1.5)

Hypoesthesia	1 (0.3)	1 (0.6)	0
Lethargy	1 (0.3)	0	1 (0.8)
Reduced facial expression	1 (0.3)	1 (0.6)	0
Tremor	4 (1.3)	0	4 (3.0)

LOCF: last observation carried forward.

Supplementary Table 2: Conversion from PP1M Mono- or Polytherapy to PP3M Mono- or Polytherapy (modified intent-to-treat population)

	Total (N=305)	LOCF endpoint symptomatic remission	
		Yes (n=172)	No (n=133)
PP1M monotherapy to PP3M monotherapy, n (%)	253 (83.0)	143 (83.1)	110 (82.7)
PP1M monotherapy to PP3M polytherapy, n (%)	0	0	0
PP1M polytherapy to PP3M monotherapy, n (%)	0	0	0
PP1M polytherapy to PP3M polytherapy, n (%)	52 (17.0)	29 (16.9)	23 (17.3)

Supplementary Table 3: Psychotropic medications ($\geq 1\%$) prescribed from 4 months prior to initiation of PP3M treatment until the end of the study (modified intent-to-treat population)

	Total (N=305)	LOCF endpoint symptomatic remission	
		Yes (n=172)	No (n=133)
Patients prescribed ≥ 1 psychotropic medication before PP3M start, n (%)	130 (42.6)	74 (43.0)	56 (42.1)
Biperiden	25 (8.2)	14 (8.1)	11 (8.3)
Olanzapine	16 (5.2)	9 (5.2)	7 (5.3)
Diazepam	11 (3.6)	8 (4.7)	3 (2.3)
Lorazepam	11 (3.6)	7 (4.1)	4 (3.0)
Quetiapine fumarate	9 (3.0)	6 (3.5)	3 (2.3)
Risperidone	9 (3.0)	4 (2.3)	5 (3.8)
Valproate sodium	9 (3.0)	6 (3.5)	3 (2.3)
Aripiprazole	7 (2.3)	4 (2.3)	3 (2.3)
Benzatropine mesilate	7 (2.3)	4 (2.3)	3 (2.3)
Trihexyphenidyl	7 (2.3)	5 (2.9)	2 (1.5)
Procyclidine hydrochloride	6 (2.0)	5 (2.9)	1 (0.8)
Sertraline	6 (2.0)	5 (2.9)	1 (0.8)
Clonazepam	5 (1.6)	2 (1.2)	3 (2.3)

Lithium carbonate	5 (1.6)	2 (1.2)	3 (2.3)
Quetiapine	5 (1.6)	4 (2.3)	1 (0.8)
Sertraline hydrochloride	5 (1.6)	1 (0.6)	4 (3.0)
Trihexyphenidyl hydrochloride	5 (1.6)	4 (2.3)	1 (0.8)
Alprazolam	4 (1.3)	3 (1.7)	1 (0.8)
Amisulpride	4 (1.3)	0	4 (3.0)
Chlorpromazine	4 (1.3)	3 (1.7)	1 (0.8)
Escitalopram	4 (1.3)	4 (2.3)	0
Estazolam	4 (1.3)	3 (1.7)	1 (0.8)
Venlafaxine hydrochloride	4 (1.3)	2 (1.2)	2 (1.5)
Haloperidol	3 (1.0)	3 (1.7)	0
Paliperidone	3 (1.0)	1 (0.6)	2 (1.5)
Zolpidem	3 (1.0)	0	3 (2.3)
Zopiclone	3 (1.0)	1 (0.6)	2 (1.5)

LOCF: last observation carried forward; PP3M: paliperidone palmitate 3-monthly.

Supplementary Table 4: Psychotropic medications ($\geq 1\%$) prescribed after the initiation of PP3M treatment until the end of the study (modified intent-to-treat population)

	Total (N=305)	LOCF endpoint symptomatic remission	
		Yes (n=172)	No (n=133)
Patients prescribed ≥ 1 psychotropic medication after PP3M start, n (%)	130 (42.6)	74 (43.0)	56 (42.1)
Lorazepam	16 (5.2)	10 (5.8)	6 (4.5)
Paliperidone	14 (4.6)	2 (1.2)	12 (9.0)
Risperidone	12 (3.9)	5 (2.9)	7 (5.3)
Olanzapine	11 (3.6)	4 (2.3)	7 (5.3)
Biperiden	10 (3.3)	6 (3.5)	4 (3.0)
Diazepam	8 (2.6)	5 (2.9)	3 (2.3)
Clonazepam	6 (2.0)	4 (2.3)	2 (1.5)
Zolpidem tartrate	6 (2.0)	3 (1.7)	3 (2.3)
Alprazolam	5 (1.6)	3 (1.7)	2 (1.5)
Quetiapine fumarate	5 (1.6)	1 (0.6)	4 (3.0)
Trihexyphenidyl	5 (1.6)	0	5 (3.8)
Zolpidem	5 (1.6)	2 (1.2)	3 (2.3)
Aripiprazole	4 (1.3)	0	4 (3.0)

Paracetamol	4 (1.3)	0	4 (3.0)
Procyclidine hydrochloride	4 (1.3)	3 (1.7)	1 (0.8)
Quetiapine	4 (1.3)	2 (1.2)	2 (1.5)
Sertraline hydrochloride	4 (1.3)	2 (1.2)	2 (1.5)
Amisulpride	3 (1.0)	2 (1.2)	1 (0.8)
Benzatropine mesilate	3 (1.0)	2 (1.2)	1 (0.8)
Mirtazapine	3 (1.0)	1 (0.6)	2 (1.5)
Phenazepam	3 (1.0)	0	3 (2.3)
Zopiclone	3 (1.0)	0	3 (2.3)

LOCF: last observation carried forward; PP3M: paliperidone palmitate 3-monthly.